Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].

导出 LinkOut

翻译打印收藏纠错

作者： Jonathan,Oh ^[1] ; Minal,Barve ^[1] ; Neil,Senzer ^[2] ; Phylicia,Aaron ^[3] ; Luisa,Manning ^[3] ; Gladice,Wallraven ^[3] ; Ernest,Bognar ^[3] ; Laura,Stanbery ^[3] ; Staci,Horvath ^[3] ; Meghan,Manley ^[3] ; John,Nemunaitis ^[3] ; Adam,Walter ^[3] ; Rodney P,Rocconi ^[4]

作者单位： Texas Oncology, P.A., Dallas, TX, United States. ^[1] Mary Crowley Cancer Research Centers, Dallas, TX, United States. ^[2] Gradalis, Inc., Carrolton, TX, United States. ^[3] ProMedica, Toledo, OH, United States. ^[4] University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States. ^[5]

DOI 10.1016/j.gore.2021.100740

PMID 34095420

发布时间 2021-06-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Gynecologic oncology reports

2021年36卷

100740页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].

Gynecologic oncology reports

相似文献

Gynecologic oncology reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].

Gynecologic oncology reports

相似文献

Gynecologic oncology reports

相关期刊

检索历史清除